Allergan, a multi-specialty healthcare company, and Medytox, a research-based biopharmaceutical company, have entered into a license agreement. Allergan will pay Medytox an upfront payment of $65 million and Medytox will grant Allergan exclusive rights, worldwide outside of Korea, to develop and, if approved, commercialize neurotoxin product candidates currently in development, including a potential liquid-injectable product.

Allergan has also agreed to make additional contingent payments, including up to $116.5 million upon achieving development milestones, up to $180.5 million upon achieving commercialization milestones and royalties on product sales.